Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.

By Cheung A P   Lu J K   Chang R J  

Human Reproduction, Vol. 12, Iss. 6, 1997-06 ,pp. : 1156-1164

Oxford University Press

Access to resources Recommend Favorite

Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite

Endocrinology: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy

By Blumenfeld Zeev  

Human Reproduction, Vol. 11, Iss. 8, 1996-08 ,pp. : 1620-1626

Oxford University Press

Access to resources Recommend Favorite

17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.

By Sahin Y   Keleştimur F  

Human Reproduction, Vol. 12, Iss. 5, 1997-05 ,pp. : 910-913

Oxford University Press

Access to resources Recommend Favorite

Previous cycle cancellation due to poor follicular development as a predictor of ovarian response in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment

By Peñarrubia Joana  

Human Reproduction, Vol. 20, Iss. 3, 2005-03 ,pp. : 622-628

Oxford University Press

Access to resources Recommend Favorite